Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Bioavailability of Sotagliflozin
NCT03174548Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotagliflozin in diabetes mellitus (DM) (3 arms), sponsored by Sanofi. Primary endpoints: Maximum plasma drug concentration and Area under curve. Started Jun 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03174548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174548.